Skip to main content
OpenTrials
Active, not recruiting

NCT Number: NCT01878669

Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention

The aim of this study is to evaluate the effects of N-acetyl cysteine on periprocedural myocardial infarction and major cardiac and cerebral events in patients undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy.

Active, not recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Suleyman Demirel University

Isparta, Mediterranean Region, 32260, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients > 18 years old undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy (Mehran Score ≥ 5)

Exclusion criteria

  • Primary percutaneous coronary intervention
  • Low risk for contrast induced nephropathy (Mehran Score < 5)
  • Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...)
  • Infection
  • Pregnancy, Lactation
  • Renal failure requiring dialysis
  • Hepatic failure
  • History allergy for NAC
  • History of Asthma
  • Chronic nitrate usage
  • Malignancy
  • Use of corticosteroids
  • Leukocytosis,Thrombocytosis,Anemia
  • Blood pressure of >180/100mmHg despite anti-hypertensive therapy

Treatment and study plan

N-acetyl cysteine

Drug

Saline

Drug

Primary outcomes

  1. periprocedural myocardial infarction

    Time frame: postprocedural 3-6 h

Secondary outcomes

  1. NAC side effects (Asthma exacerbation, pruritus, dyspnea)

    Time frame: during hospitalization at 48 hours

  2. major cardiac and cerebral events

    Time frame: 1 year follow-up

Sponsors and collaborators

Lead sponsor

Suleyman Demirel University

Other

Registry information

Official study title

Effects of N-acetyl Cysteine on Periprocedural Myocardial Infarction and Major Cardiac and Cerebral Events in Patients Undergoing Percutaneous Coronary Intervention

Acronym: EASE-PCI

Important dates

Study start
2013
Primary completion
2017
Study completion
2026
First posted
Jun 17, 2013
Registry last updated
May 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.